RHHBY (Roche Holding AG) Interest Expense : $-1,377 Mil (TTM As of Jun. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Roche Holding AG Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Roche Holding AG's interest expense for the six months ended in Jun. 2024 was $ -790 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was $-1,377 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Roche Holding AG's Operating Income for the six months ended in Jun. 2024 was $ 10,149 Mil. Roche Holding AG's Interest Expense for the six months ended in Jun. 2024 was $ -790 Mil. Roche Holding AG's Interest Coverage for the quarter that ended in Jun. 2024 was 12.85. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Roche Holding AG Interest Expense Historical Data

The historical data trend for Roche Holding AG's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Interest Expense Chart

Roche Holding AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-805.01

-622.47

-454.94

-740.66

-1,152.87

Roche Holding AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Interest Expense	Get a 7-Day Free Trial															-312.31	-415.41	-543.09	-587.42	-789.89

Roche Holding AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1,377 Mil.

Roche Holding AG (OTCPK:RHHBY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Roche Holding AG's Interest Expense for the six months ended in Jun. 2024 was $-790 Mil. Its Operating Income for the six months ended in Jun. 2024 was $10,149 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was $31,797 Mil.

Roche Holding AG's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2024 )	/	Interest Expense (Q: Jun. 2024 )
	=	-1	*	10148.803	/	-789.886
	=	12.85

The higher the ratio, the stronger the company's financial strength is.

Roche Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RHHVF:USA RHHBF:USA ROG N:Mexico ROz:UK ROGz:UK 0TDF:UK 0QQ6:UK 0QOK:UK RHO6:Germany ROG:Switzerland RO:Switzerland

Address

Grenzacherstrasse 124, Basel, CHE, 4070

Website

https://www.roche.com

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.